Viking Therapeutics
About Viking Therapeutics
Viking Therapeutics (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic and endocrine disorders. The company operates with a lean organizational structure, outsourcing manufacturing and certain research functions to maintain capital efficiency while advancing multiple clinical programs.
The company's lead asset, VK2735, is a dual agonist of GLP-1 and GIP receptors designed to treat obesity. In clinical trials, VK2735 has demonstrated significant weight reduction in participants across both injectable and oral formulations. Viking is also developing VK2809, an orally available thyroid hormone receptor beta agonist that targets non-alcoholic steatohepatitis (NASH) and liver fibrosis. VK2809 selectively activates the beta subtype of the thyroid hormone receptor, which plays a central role in hepatic lipid metabolism.
Additional pipeline candidates include VK0214, a thyroid receptor beta agonist in development for X-linked adrenoleukodystrophy, a rare neurological condition. Viking's research programs share a common emphasis on targeting nuclear hormone receptors and peptide-based mechanisms to address conditions with limited approved treatment options. The company is headquartered in San Diego, California.
Similar to Viking Therapeutics
More Companies →Why Viking Therapeutics Matters
Viking Therapeutics operates in the rapidly expanding metabolic disease space, where GLP-1 receptor-based therapies have emerged as a major drug class for obesity treatment. The company's dual GLP-1/GIP agonist approach positions it alongside larger competitors pursuing next-generation weight loss drug development. Its oral formulation efforts address a key area of industry focus as companies work to move beyond injectable delivery.
